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Obstructive sleep apneaChronic intermittent hypoxia (CIH) causes atherosclerosis in mice fed a high cholesterol diet (HCD). The
mechanisms by which CIH promotes atherosclerosis are incompletely understood. This study deﬁned the
mechanistic role of NF-κB pathway in CIH+HCD induced atherosclerosis. Wild type (WT) and mice deﬁcient
in the p50 subunit of NF‐κB (p50‐KO) were fed normal chow diet (ND) or HCD, and exposed to sham or CIH.
Atherosclerotic lesions on the en face aortic preparation and cross‐sections of aortic root were examined. In
WT mice, neither CIH nor HCD exposure alone caused, but CIH+HCD caused evident atherosclerotic lesions
on both preparations after 20 weeks of exposure. WT mice on ND and exposed to CIH for 35.6 weeks did not
develop atherosclerotic lesions. P50 gene deletion diminished CIH+HCD induced NF‐κB activation and
abolished CIH+HCD induced atherosclerosis. P50 gene deletion inhibited vascular wall inﬂammation, re-
duced hepatic TNF‐α level, attenuated the elevation in serum cholesterol level and diminished macrophage
foam cell formation induced by CIH+HCD exposure. These results demonstrate that inhibition of NF‐κB ac-
tivation abrogates the activation of three major atherogenic mechanisms associated with an abolition of
CIH+HCD induced atherosclerosis. NF‐κB may be a central common pathway through which CIH+HCD ex-
posure activates multiple atherogenic mechanisms, leading to atherosclerosis.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Obstructive sleep apnea (OSA) is one of the most common public
health problems [1] and has been recognized as a risk factor for ath-
erosclerotic cardiovascular disease [2–6]. Epidemiological studies
have revealed a strong independent association between OSA and
coronary [2–6] and cerebral vascular disease [4–7], common conse-
quences of atherosclerosis. However, mechanisms underlying this
association remain elusive.
While OSA causes many physiological perturbations, including hy-
percapnia, arousals, and intrathoracic pressure swings [8,9], long term,
repetitive episodes of hypoxia followed by re-oxygenation (chronic in-
termittent hypoxia, CIH) is believed to be a major contributing factor torter A1; ApoE-KO, mice lacking
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l rights reserved.OSA-associated cardiovascular disorders [10]. The focus has therefore
been on understanding how CIH causes atherosclerosis.
Several prior studies have demonstrated that 10–12 weeks of CIH
exposure induced atherosclerosis in wild type (WT) mice or mice de-
ﬁcient in apolipoprotein E gene (ApoE-KO) on a high cholesterol diet
(HCD) [11–14]. Exposure of ApoE-KOmice on normal chow diet (ND)
to CIH for 2 weeks exacerbated the progression of pre-existing ath-
erosclerotic lesions [15]. CIH exposure causes hypercholesterolemia
and dyslipidemia [11,12,16], systemic and vascular inﬂammation
[17–22], hypertension [10,23] and lipid peroxidation [11–13]. Most
recent studies suggest that CIH or OSA impaired triglyceride clearance
[24,25]. All of those factors may mediate or contribute to CIH-induced
atherosclerosis.
Despite all the evidence, the molecular events orchestrating the
activation of multiple atherogenic pathways that lead to atheroscle-
rosis remain largely unexplored. NF-κB is a multi-faceted transcrip-
tion factor involved in numerous physiological and pathological
processes. In addition to mediating inﬂammatory and immune re-
sponses [26], NF-κB has been implicated in numerous pathological
conditions, including hypertension [27], diabetes [28], obesity [29]
and insulin resistance [30], all of which are well-known atherogenic
factors. Ryan et al. ﬁrst demonstrated that intermittent hypoxia/
reoxygenation selectively activated NF-κB in cultured cells [19]. We
and others have shown that CIH activated NF-κB in vascular tissue
in mice in an exposure time-dependent manner [17,22]. Patients
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and monocytes [18] and elevated serum levels of NF-κB-dependent
gene products [18–20]. Thus, the NF-κB pathway could be a central
common pathway through which CIH activates multiple atherogenic
mechanisms, leading to atherosclerosis. To test this hypothesis, we
inhibited NF-κB activation using mice deﬁcient in p50 gene (p50-KO).
The lack of p50 protein in p50-KOmice diminishes p50/p50 homodimers
and reduces nuclear translocation of p50/p65 heterodimer.We examined
the effects of NF-κB inhibition on CIH+HCD-induced atherosclerosis
and on the activation of multiple atherogenic mechanisms.We chose
to use p50-KOmice, because this mouse strain can tolerate the harsh
experimental condition of long term CIH exposure, compared to
other NF-κBmutantmouse strains.We demonstrated that p50 gene de-
letion diminished CIH+HCD-induced NF-κB activation, eliminated
CIH+HCD induced atherosclerosis, and inhibited CIH+HCD-induced
activation of three major atherogenic mechanisms. Our data suggest
that activation of NF-κB pathway plays a central role in CIH+HCD in-
duced atherosclerosis.
2. Materials and methods
2.1. Animal groups and CIH exposure protocol
WT and p50-KO mice were purchased from Jackson laboratory.
Animal study protocols were approved by the Feinstein Institute for
Medical Research animal care and use committee. We studied 8 groups
of mice (all on C57BL/6 genetic background): WT-ND-sham, WT-ND–
CIH, WT-HCD–sham, WT-HCD–CIH, p50-KO-ND-sham, p50-KO-ND–
CIH, p50-KO-HCD-sham and p50-KO-HCD–CIH groups. Mice were fed
ND (5.0% fat, 0.02% cholesterol, 4 kcal/g) or HCD (15.8% fat, 1.25%
cholesterol, 4 kcal/g) starting at 7 weeks of age and exposed to sham
or CIH.
To mimic the cyclic episodes of hypoxia and reoxygenation seen in
OSA patients, we placed sham and CIH exposed mice in separate, but
identical plexiglass exposure chambers that we have previously de-
scribed in detail [17]. The fractional oxygen concentration (FcO2) in
the exposure chamber was reduced to a nadir of 6.0–6.5%, stabilized
at that level for 5–7 s, and then gradually increased to 21% over the
next 30 seconds by infusion of nitrogen or air into the chambers by
computer controlled solenoid valves. This cycle was repeated every
minute over 8 hours during the animals’ diurnal sleep period for
days according to experimental design. Sham exposed mice were ex-
posed to similar handling but room air was used instead of nitrogen.
To characterize the oxygen proﬁle of our CIH protocol, a cohort of
5 mice was exposed to CIH for 5 days, anesthetized with tribromo-
ethanol, and carotid artery cannulated. Arterial blood was collected
when FcO2 in the chamber was at 21% and 6.0–6.5%, respectively,
and blood gas analyzed. Another cohort of 5 mice was exposed to
CIH for 5 days and SpO2 measured using mouse pulse oximeter at
day 6.
2.2. Tissue harvest and atherosclerotic lesions analysis
At conclusion of exposure protocols, mice were fasted for 8 hours
and sacriﬁced, and blood, heart, aorta and liver collected. For en face
analysis of atherosclerotic lesions on aorta, the aortic tree was per-
fused with PBS, opened longitudinally starting from approximately
5 mm distal to the aortic root to the iliac bifurcation, ﬁxed in a mix-
ture of 5% sucrose and 10% buffered formalin, pinned to a wax pan,
and stained with Sudan IV solution [31,32].
For analysis of atherosclerotic lesions on cross section of aortic
root, the heart was embedded in OCT medium and serial 6-μm cryo-
stat heart/aortic sections centered around aortic valves prepared.
These sections were stained with Oil Red O (ORO) and hematoxylin
as previously described [31,32]. Images of the cross sections and
en face aortic preparations were captured using a Nikon DS Camera.The atherosclerotic lesion area was quantiﬁed in a blind fashion
using Nikon NIS-Elements Research Software and expressed as a
percentage of the total area of the entire aorta or as 103 μm on cross
section of aortic root.
2.3. Foam cell formation assay
Peritoneal macrophages were isolated by peritoneal lavage of mice
4 days after intraperitoneal injection of thioglycolate medium. Equal
numbers of cells from each groupwere centrifuged onto cytospin slides
and stained with ORO and hematoxylin. ORO-positive foam cells were
counted and expressed as percentage of total cell counts.
2.4. Electrophoretic mobility shift assay (EMSA)
Nuclear and cytoplasmic proteins were extracted from liver, and
NF-κB binding activity was measured by EMSA using 32P-labeled
NF-κB consensus oligonucleotide as we have previously described
[33]. The speciﬁcity of NF-κB DNA binding was conﬁrmed in competi-
tion reactions in which 50-fold molar excess unlabelled NF-κB oligonu-
cleotide was added to the binding reaction 10 minutes prior to the
addition of labeled probe.
2.5. Western blotting
Equal amounts of proteins were separated on 7.5–10% SDS-PAGE slab
gel under denaturing conditions. Tissue levels of TNF receptor-associated
factor 3 (TRAF3), p100, I-κBα, ATP-binding cassette transporter A1
(ABCA1), scavenger receptor class B1 (SR-B1) and actin were detected
by Western blotting as we previously described [34].
2.6. Measurement of serum levels of lipids, lipoproteins and cytokines
Serum levels of total cholesterol, HDL and LDL/VLDL cholesterol
and triglycerides were measured using commercial kits (BioAssay,
Pointe Scientiﬁc). Serum levels of interleukin-6 (IL6), chemokine
ligand (CCL) 2 and TNF-α, and hepatic level of TNF-α were measured
using ELISA kits (eBiosciences).
2.7. Immunohistochemical staining
Cryosections (6 μm) were prepared, ﬁxed, permeabilized, blocked
in blocking solution, and incubated with anti-iNOS (inducible nitric
oxide synthase) or anti-Mac3 antibodies (Santa Cruz) as we previously
described [34]. Speciﬁc bindingwas detected with biotinylated second-
ary antibody-horseradish peroxidase complexes using VECTASTAIN®
Elite ABC kits (Vector Laboratories). Antigen-antibody complexes
were visualized using 3′, 3′-diamino benzidine (Vector Laboratories).
Sections were counterstained with hematoxylin, mounted and viewed
under light microscope. Total and iNOS (or MAC3) positive areas were
quantiﬁed in 5 random microscopic ﬁelds per aortic section under the
same magniﬁcation. The accumulated iNOS (or MAC3) positive area
from the 5 microscopic ﬁelds was divided by the accumulated total
analyzed area of aortic wall.
2.8. Q-RT-PCR
Total RNA was extracted using TRIZOL reagent (Invitrogen, CA) and
treatedwith RNase-free DNase I to remove traces of genomic DNA. Each
RNA samplewas subjected to quantitative reverse transcription and po-
lymerase chain reaction (Q-RT-PCR) using TaqMan One-Step RT-PCR
Master Mix Reagents (Applied Biosystems) and gene speciﬁc primers
and probes. The gene speciﬁc probes were: #78 for hydroxy-3-
methyl-glutaryl-CoA reductase (HMGCR), #64 for LDL receptor
(LDLr), #1 for ABCA1 and #2 for SR-B1 (Roche Universal Probe Library,
Mannheim, Germany). Primers used were: HMGCR, forward, 5′-tgattgg
Table 1
Mean body weight and serum lipid and lipoprotein levels.
N Body weight Triglyceride Cholesterol HDL-C LDL-C
(g) (mg/dl) (mg/dl) (mg/dl) (mg/dl)
WT-ND-sham 8 27.6±1.8 39.1±3.2 48.5±4.0 53.3±7.0 22.5±4.5
WT-HCD-sham 8 24.3±1.0 73.8±40.4 166.7±17.2* 51.8±5.0 71.9±9.7#
WT-ND-CIH 8 23.6±0.7 43.2±7.5 44.4±6.3 50.8±10.7 24.9±5.4
WT-HCD–CIH 8 25.1±1.1 84.3±45.4 176.6±20.4* 49.7±6.4 83.2±15.3#
p50-KO-ND-sham 6 29.0±1.8 35.3±10.2 62.8±4.9 70.7±5.4 22.3±1.9
p50-KO-HCD-sham 6 26.7±1.6 20.0±3.7 145.6±13.4* 51.1±4.6 59.1±7.6#
p50-KO-ND-CIH 6 23.6±0.6* 27.3±3.0 56.5±3.9 58.1±8.7 16.2±1.7
p50-KO-HCD–CIH 6 21.4±1.0* 23.9±7.1 110.5±10*‡ 27.8±4.4#‡ 77.8±25.3#
*,signiﬁcantly different from their respective ND-Sham group. #, signiﬁcantly different from their respectiveND-Sham andND-CIH groups. ‡, signiﬁcantly different fromWT-HCD–CIH group.
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forward, 5′-gatggctatacctacccctcaa-3′ and reverse, 5′-tgctcatgccaca
tcgtc-3′, ABCA1, forward, 5′-gcagatcaagcatcccaact-3′ and reverse, 5′-cc
agagaatgtttcattgtcca; SR-B1, forward, 5′-gcccatcatctgccaact-3′ andFig. 1. P50 gene deletion abolishes CIH+HCD induced atherosclerosis. Wild type (WT) mi
cholesterol diet (HCD) starting at 7 weeks of age, and exposed to sham (ND‐Sham and HCD
en face aortic preparations and cross‐sections of aortic root were prepared and stained with
aortic preparations showing that Sudan IV‐stained atherosclerotic lesions were detected on
sections of aortic root showing that ORO‐stained atherosclerotic lesions were seen only on s
preparation was quantiﬁed and expressed as a percentage of total aortic area. Means±SEM
lesion area on cross-sections of aortic root was quantiﬁed and expressed as ×103 μm. Meanreverse, 5′-tcctgggagccctttttact-3′. Q-RT-PCR Was performed in 7900
HT thermocycler (Applied Biosystems). Results were analyzed using
the delta–delta Ct method. Expression of speciﬁc genes was normalized
to β-actin mRNA (TaqMan RNA Reagents, Applied Biosystems).ce and mice deﬁcient in p50 gene (p50‐KO) were fed normal chow diet (ND) or high
‐Sham) or CIH (ND‐CIH and HCD−CIH). At 20 weeks after sham or CIH exposure, the
Sudan IV and Oil Red O (ORO), respectively. A: Representative photographs of en face
ly on aorta from WT‐HCD–CIH group of mice. B: Representative photographs of cross‐
ection fromWT‐HCD–CIH group of mice. C: Atherosclerotic lesion area on en face aortic
of 8 animals in each group. *pb0.05, compared with other 7 groups. D: Atherosclerotic
s±SEM of 8 animals in each group. *pb0.05, compared with other 7 groups.
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Data were expressed as mean±SEM. and analyzed using un-
paired t test or Mann–Whitney rank test for comparing two groups.
For comparing multiple groups, data were analyzed using ANOVA
or Kruskal–Wallis rank test, followed by Holm–Sidak method or
Student–Newman–Keuls Method for post hoc analysis. The null hy-
pothesis was rejected at 5% level.3. Results
3.1. Characterization of the mouse model of CIH
Body weights were comparable among the 8 groups at the
commencement of the exposure protocols. At the completion of the
exposure protocols (20 weeks), mice in experimental groups had
lower body weights, compared to respective ND-sham groups. Statisti-
cally signiﬁcant differences were noted between ND-sham and ND-CIH
or ND-sham and HCD−CIH groups of p50-KO mice (Table 1).
Blood gas analysis on a group of anesthetized mice andmouse pulse
oximeter measurement on another group of awake mice showed that a
decline in fractional oxygen concentration (FcO2) from 20.9% to a nadir
of 6% over 30-s hypoxic period resulted in a drop in PaO2 from 96.5±Fig. 2. Long-term CIH exposure does not cause atherosclerosis. WTmicewere fed ND and
exposed to sham (ND‐Sham) or CIH (ND‐CIH) for 35.6 weeks. En face aortic preparations
and cross‐sections of aortic root were prepared and stained with Sudan IV and ORO, re-
spectively. A and B: Representative photographs of en face aortic preparations and
cross‐sections of aortic root. Sudan IV‐ or ORO‐positive atherosclerotic lesion was hardly
detected following 8.3 months of CIH exposure. C: Atherosclerotic lesion area on en face
aortic preparation was quantiﬁed and expressed as a percentage of total aortic area.
Means±of 5 animals in each group.3.8 to 45.8±1.7 mm Hg, and a drop in pulse oximeter oxygen satura-
tion (SpO2) from 97.7±0.3 to 79.3±1.2%. Our result is consistent
with a report showing that PaO2 dropped from 88±3 at room air to
47±2 mm Hg at the nadir of 6% O2 in conscious mice [35]. Our
mouse model produces a level of hypoxia that resembles moderate to
severe OSA, and a rate of hypoxia (60 events/hour) which simulates
severe OSA [8,9].3.2. Effects of CIH exposure on the development of atherosclerosis in WT
mice
A prior study showed that C57 WT mice on ND had no detectable
atherosclerotic lesions after 12 weeks of CIH exposure [11]. It is
possible that exposure to CIH for longer periods of time may cause
atherosclerosis. To examine this possibility, we exposed WT mice
on ND to sham or CIH for 20 weeks. After 20 weeks of CIH exposure,
atherosclerotic lesions were not detected on en face aorticFig. 3. P50 gene deletion blocks CIH-, HCD- or CIH+HCD-induced NF-κB activation. Mice
were fed ND orHCD and exposed to sham (ND‐Sham,HCD‐Sham) or CIH (ND‐CIH, HCD−
CIH) for 30 days. Hepatic NF‐κB DNA binding activity was measured by electrophoretic
mobility shift assay (EMSA) and hepatic levels of TNF receptor associate factor 3
(TRAF3), p100/NF‐κB2, I‐κBα and actin proteins were determined by Western blot.
A: EMSA autoradiograph showing that p50 gene deletion blocks CIH (top), HCD (middle)
or CIH+HCD (bottom) induced NF‐κB activation. B: Characterization of CIH‐, HCD‐ or
CIH+HCD‐induced NF‐κB activation pathway.Western blot photographs showing hepat-
ic levels of TRAF3, p100, I‐κBα and actin proteins. CIH, HCD or CIH+HCD did not cause
TRAF3 and p100 degradation, but signiﬁcantly reduced tissue level of I‐κBα, illustrating
that CIH, HCD and CIH+HCD activate NF‐κB via the canonical pathway.
Fig. 4. Effects of CIH and p50 gene deletion on serum levels of markers of systemic inﬂammation and hepatic level of TNF-α. Mice on ND or HCD were exposed to sham (ND‐Sham,
HCD‐Sham) or CIH (ND‐CIH, HCD−CIH) for 9 weeks. Serum levels of IL‐6 (A), CCL2 (B) and TNF‐α (C), and hepatic level of TNF‐α (D) were determined using ELISA kit. CIH and/or
HCD exposure increased serum level of IL‐6, but not TNF‐α. CIH+HCD and p50 gene deletion had different effects on serum and hepatic TNF‐α. Means±SEM of 6 mice each group.
*pb0.05, compared to respective ND‐Sham group. #pb0.05, compared to WT‐HCD‐Sham or WT‐HCD–CIH group.
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ND-sham vs ND-CIH). To further clarify that CIH exposure does not
cause atherosclerosis in WT mice, we exposed another cohort of WT
mice on ND to CIH for 35.6 weeks. The long-term exposure to CIH did
not cause atherosclerotic lesions (Fig. 2).
Next, we examined if HCD alone causes atherosclerosis. Atheroscle-
rotic lesions were not detectable on en face aortic preparations or
cross-sections of aortic root from WT mice fed HCD for 20 weeks
(Fig. 1A and B,WT,ND-shamvsHCD-sham). By contrast, atherosclerotic
lesionswere detected on both preparations fromWT-HCD–CIH group of
mice (Fig. 1A and B, WT, ND-sham vs HCD−CIH). Fig. 1C and D (left
panel) showed quantiﬁcation of atherosclerotic lesion areas on en face
aortic preparations and on the cross-sections of aortic root. Thus, nei-
ther CIH nor HCD alone causes atherosclerosis, but a combination of
the two causes pronounced atherosclerotic lesions in C57BL WT mice.
3.3. P50 gene deletion abolishes CIH+HCD-induced atherosclerosis
To deﬁne the role of NF-κB activation in CIH+HCD-induced
atherosclerosis, we compared atherosclerotic lesion areas between
WT and p50-KO mice. After 20 weeks of CIH exposure, atheroscle-
rotic lesions were detected on the en face aortic preparations and
cross-sections of aortic root from WT-HCD–CIH group (Fig. 1A
and B, WT, HCD−CIH). The CIH+HCD-induced atherosclerosis
was abolished in p50-KO-HCD–CIH group of mice (Fig. 1A and B,
HCD−CIH, WT vs p50-KO), indicating that NF-κB activation plays
a pivotal role in CIH+HCD-induced atherosclerosis.
CIH-induced NF-κB activation, vascular inﬂammation and
dyslipidemia exhibited different time course proﬁles. NF-κBactivation and vascular inﬂammation peaked at 4–5 weeks and
8–10 weeks, respectively. To demonstrate an effect of NF-κB inhibition,
measurement of each response has to be timed to catch the response at
its peak. Each response was studied at different time point in subse-
quent studies.3.4. P50 gene deletion blocks CIH- and/or HCD-induced NF-κB activation
To examine themechanisms bywhich p50 KO abolishes CIH+HCD-
induced atherosclerosis, we ﬁrst wanted to conﬁrm if p50 gene deletion
blocks CIH+HCD-induced NF-κB activation. A preliminary study
showed that the time course proﬁles of CIH-induced NF-κB activation
and the subunit compositions of CIH-induced NF-κB complex are iden-
tical between aorta and liver. We analyzed NF-κB activation pathway
using hepatic proteins to save aortas for more important analyses,
such as atherosclerotic lesion analyses. Liver is a major target of CIH ex-
posure and alteration in liver gene expression plays important roles in
CIH-induced dyslipidemia and atherosclerosis [11,12,16]. Compared to
ND-sham group, ND-CIH, HCD-sham or HCD−CIH group of WT mice
showed a markedly increased hepatic NF-κB activity, which was signif-
icantly inhibited in all the three groups of p50-KO mice (Fig. 3A), dem-
onstrating that p50 gene deletion blocks CIH- and/or HCD-induced
NF-κB activation.
Western blot analysis revealed that CIH, HCD or CIH+HCD exposure
had no effects on hepatic levels of TRAF3 and p100 proteins (Fig. 3B,
TRAF3 and p100), two key signaling molecules of the noncanonical
NF-κB activation pathway [26,36], but signiﬁcantly reduced hepatic
level of I-κBα protein, key signaling molecule of the canonical NF-κB
1655D. Song et al. / Biochimica et Biophysica Acta 1822 (2012) 1650–1659activation pathway [26,36] (Fig. 3B, I-κBα). Thus, CIH and/orHCD activate
NF-κB via the canonical pathway in WT C57BL/6 mice.
3.5. P50 gene deletion inhibits CIH+HCD-induced vascular wall
inﬂammation
We compared serum levels of TNF-α, IL6 and chemokine ligand
(CCL)2, and aortic iNOS expression between WT and p50-KO mice.
CCL2, also known as monocyte chemotactic protein-1, mediates mono-
cyte recruitment into developing atherosclerotic lesions. We chose to
study those NF-κB-regulated gene products because of their established
roles in atherogenesis [37–40]. CIH, HCD or HCD+CIH exposure all sig-
niﬁcantly increased serum level of IL6 (Fig. 4A). HCD+CIH, but not CIH
or HCD alone, signiﬁcantly increased serum level of CCL2 (Fig. 4B). P50
gene deletion had no signiﬁcant effects on CIH and/or HCD induced
changes in serum levels of the 2 cytokines (Fig. 4A and B). CIH/HCD
and p50 gene deletion had different effects on serum and hepatic levels
of TNF-α. HCD or HCD+CIH exposure did not signiﬁcantly increase
serum level (Fig. 4C), but signiﬁcantly increased hepatic level of
TNF-α (Fig. 4D), which was inhibited by p50 gene deletion (Fig. 4D).
Thus, CIH and/or HCD exposure had variable effects on serum levels of
markers of systemic inﬂammation and p50 gene deletion did not alter
the effects.
We next examined if p50 KO affects CIH- and/or HCD-induced
vascular wall inﬂammation. IHC staining showed that CIH or HCD
increased, and CIH+HCD further increased aortic iNOS expression
(Fig. 5, WT, ND-sham vs ND-CIH, HCD-sham or HCD−CIH). P50
gene deletion signiﬁcantly inhibited iNOS expression caused by eachFig. 5. P50 gene deletion inhibits CIH-, HCD- or CIH+HCD-induced aortic iNOS expres-
sion. Mice were fed ND or HCD and exposed to sham (ND‐Sham, HCD‐Sham) or CIH
(ND‐CIH, HCD−CIH) for 9 weeks. Aortic iNOS protein expression was detected by IHC
staining using iNOS speciﬁc antibody. A: IHC staining photographs showing that CIH
(WT, ND‐sham vs ND‐CIH), HCD (WT, ND‐sham vs HCD‐sham) and HCD+CIH (WT,
ND‐sham vs HCD−CIH) increased aortic iNOS expression, and that p50 gene deletion
inhibited CIH‐ (ND‐CIH, WT vs p50‐KO), HCD‐ (HCD‐sham, WT vs p50‐KO) and
HCD+CIH‐induced (HCD−CIH, WT vs p50‐KO) aortic iNOS expression. B: Quantitative
analysis of the iNOS‐positive area expressed as a percentage of total analyzed area.
Means±SEM of 5 mice in each group. *pb0.05, compared to respective ND‐sham group.
#pb0.05, compared to WT‐ND‐CIH, WT‐HCD‐sham or WT‐HCD–CIH group.stimulus (Fig. 5). Likewise, CIH or HCD signiﬁcantly increased and
CIH+HCD further increased aortic inﬁltration of Mac3-positive macro-
phages (Fig. 6, WT, ND-sham vs ND-CIH, HCD-sham or HCD−CIH),
which was attenuated by p50 gene deletion (Fig. 6). Thus, p50 gene
deletion inhibits vascular wall inﬂammation.3.6. P50 gene deletion attenuates CIH+HCD-induced hypercholesterolemia
Serum levels of lipids and lipoproteins in the 8 groups of mice
were summarized in Table 1. HCD alone or CIH+HCD, but not CIH
alone, signiﬁcantly increased serum levels of total cholesterol and
LDL-cholesterol in WT mice. P50 gene deletion signiﬁcantly reduced
HCD+CIH-induced, but not HCD-induced, serum level of total choles-
terol. P50 gene deletion had no signiﬁcant effect on HCD− or
CIH+HCD-induced changes in serum LDL-cholesterol level (Table 1).3.7. P50 gene deletion prevents SR-B1 and ABCA1 down-regulation
QRT-PCR analysis revealed that CIH+HCD signiﬁcantly down-
regulated hepatic ABCA1 and SR-B1 mRNA expressions, which were
prevented by p50 gene deletion (Fig. 7A and B). Consistent with the
changes in mRNA levels, hepatic ABCA1 and SR-B1 protein expressions
were down-regulated by CIH+HCD in WT, but not in p50-KO, mice
(Fig. 7E, WT vs p50-KO). CIH+HCD and p50 gene deletion had no
signiﬁcant effects on hepatic HMGCR and LDLr mRNA expressions
(Fig. 7C and D).Fig. 6. P50 gene deletion inhibits CIH-, HCD- or CIH+HCD-induced aortic macrophage
inﬁltration. Mice were fed ND or HCD and exposed to sham (ND‐Sham, HCD‐Sham) or
CIH (ND‐CIH, HCD−CIH) for 9 weeks. Aortic macrophage inﬁltration was detected by
IHC staining using Mac3 speciﬁc antibody. A: IHC staining photographs showing that
CIH (WT, ND‐sham vs ND‐CIH), HCD (WT, ND‐sham vs HCD‐sham) and HCD+CIH
(WT, ND‐sham vs HCD−CIH) increased aortic macrophage inﬁltration, and that p50
gene deletion inhibited CIH‐ (ND‐CIH, WT vs p50‐KO), HCD‐ (HCD‐sham, WT vs p50‐
KO) and HCD+CIH‐induced (HCD−CIH, WT vs p50‐KO) aortic macrophage inﬁltra-
tion. B: Quantitative analysis of the Mac3‐positive area expressed as a percentage of
total analyzed area. Means±SEM of 5 mice in each group. *pb0.05, compared to
respective ND‐sham group. #pb0.05, compared to WT‐ND‐CIH, WT‐HCD‐sham or
WT‐HCD–CIH group.
Fig. 7. P50 gene deletion prevents CIH+HCD-induced down-regulation of ABCA1 and SR-B1 expression. Mice on ND or HCD were exposed to sham (ND‐Sham) or CIH (HCD−CIH)
for 9 weeks, and liver collected. Hepatic levels of ATP‐binding cassette transporter A1 (ABCA1), scavenger receptor class B1 (SR‐B1), LDL receptor (LDLr) and 3‐hydroxy‐3‐methyl‐
glutaryl‐CoA reductase (HMGCR) mRNAs expressions were quantiﬁed using Q‐RT‐PCR, and normalized to level of β‐actin mRNA. Hepatic levels of ABCA1 and SR‐B1 proteins were
determined by Western blot. A–D: P50 gene deletion prevents CIH+HCD‐induced ABCA1 and SR‐B1 mRNA down‐regulation. Mean±SME of 5 mice. *Pb0.05 compared with other
3 groups. E: Western blot photographs showing that p50 gene deletion prevents CIH+HCD‐induced hepatic ABCA1 and SR‐B1 protein down‐regulation. Actin: membrane for
ABCA1 or SR‐B1 blotting was re‐blotted to actin antibody.
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Neither CIH nor HCD exposure alone caused macrophage foam cell
formation, but CIH+HCD induced signiﬁcant number of macrophage
foam cells inWTmice (Fig. 8). The CIH+HCD-induced foam cell forma-
tionwas diminished in p50-KOmice (Fig. 8), indicating a pivotal role for
NF-κB in CIH+HCD induced macrophage foam cell formation.
4. Discussion
A major ﬁnding of this study is that activation of NF-κB pathway
plays a central role in CIH+HCD-induced atherosclerosis. Deletion of
p50 gene diminished CIH+HCD induced NF-κB activity and concur-
rently eliminated CIH+HCD induced atherosclerosis in C57BL/6 mice.
P50 gene deletion inhibited the activation of three major atherogenic
mechanisms, vascular inﬂammation, hypercholesterolemia and macro-
phage foam cell formation. Thus, NF-κB pathway may be a centralcommon pathway through which CIH activates multiple atherogenic
mechanisms that act synergistically to induce atherosclerosis.
NF-κB activation is driving force of inﬂammation [26]. Inﬂammation
participates in all stages of the classic atherosclerosis [41]. CIH activates
NF-κB and NF-κB-mediated inﬂammatory pathways [17–22]. However,
the causative role of NF-κB activation in CIH-induced atherosclerosis
has not been previously studied. We demonstrated here that CIH and
HCD activated NF-κB, and synergistically caused vascular inﬂammation
and atherosclerosis. Deletion of p50 gene diminished NF-κB activity,
inhibited vascular inﬂammation, and abolished atherosclerotic lesions
induced by CIH+HCD. These data demonstrate a causal role of NF-κB
activation in CIH+HCD-induced atherosclerosis.
P50 gene deletion did not signiﬁcantly reduce CIH+HCD-induced
serum levels ofmarkers of systemic inﬂammation, despite abolishing ath-
erosclerosis. P50 gene deletion signiﬁcantly inhibited CIH+HCD-induced
vascularwall inﬂammation. These results suggest that vascular inﬂamma-
tion may be a more relevant factor for CIH-evoked atherosclerosis,
Fig. 8. P50 gene deletion inhibits CIH+HCD-induced macrophage foam cell formation.
Mice on ND or HCD were exposed to sham (ND‐Sham, HCD‐Sham) or CIH (ND‐CIH,
HCD−CIH) for 9 weeks. Peritoneal macrophages were harvested, centrifuged onto
cytospin slides and stained with ORO and hematoxylin. A: Representative photographs
showing that p50 gene deletion inhibited CIH+HCD‐induced macrophage foam cell
formation. B: ORO‐positive foam cells were counted and expressed as percentage of
total cell counts. Means±SEM of 5 mice in each group. *pb0.05, compared to other 7
groups.
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thy that CIH may have different effects on systemic and local inﬂamma-
tion. A previous report showed that CIH+HCD signiﬁcantly increased
hepatic, but not serum level of TNF-α [11]. Different effects of CIH+HCD
on serum and hepatic TNF-α levels were also observed in the current
study. More importantly, we found that p50 gene deletion signiﬁcantly
reduced hepatic, but not serum TNF-α level. The discrepant effects of
CIH+HCD and p50 gene deletion on systemic and liver inﬂammation
may be related to cell type-dependent variations in sensitivity and/or
response to CIH and to NF-κB inhibition. This speculation is supported
by our previous study showing that vascular tissue is more sensitive
than other tissues to CIH in term of NF-κB activation [17].
P50 gene deletion inhibited both CIH- and HCD-induced vascular
inﬂammation, suggesting a non-speciﬁc anti-inﬂammatory effect.
However, this cannot rule out the possibility that CIH and HCD may
activate NF-κB pathway through distinct mechanisms or signaling
pathways. Further studies are needed to elucidate these mechanisms
and pathways.
Hypercholesterolemia is a major mechanism of atherosclerosis
[42]. Our demonstration that p50 gene deletion signiﬁcantly reduced
CIH+HCD-induced serum cholesterol level and concomitantly
abolished CIH+HCD-induced atherosclerosis indicates that NF-κB ac-
tivation mediates, at least partially, the atherogenic response to
CIH+HCD by causing hypercholesterolemia. To elucidate the mecha-
nistic link between NF-κB activation and hypercholesterolemia, we
examined the effects of p50 gene deletion on CIH+HCD-induced
changes in the expressions of HMGCR, the rate-limiting enzyme in
cholesterol biosynthesis, LDLr, SR-B1 and ABCA1, receptors mediating
cholesterol uptake and clearance. Neither CIH+HCD exposure norp50 gene deletion affected HMGCR and LDLr mRNA expression.
CIH+HCD down-regulated ABCA1 and SR-B1 mRNA and protein ex-
pressions and p50 gene deletion prevented the down-regulation, in-
dicating a role for NF-κB in the down-regulation. Previous studies
have shown that CIH exposure down-regulated SR-B1 protein expres-
sion [16], and that oxidized LDL and cytokine down-regulated ABCA1
expression in an NF-κB-dependent manner [43]. Collectively, these
results support the contention that CIH activates NF-κB, which
down-regulates SR-B1 and ABCA1 expression, resulting in a perturba-
tion in cholesterol clearance and hypercholesterolemia.
We demonstrated for the ﬁrst time that CIH exposure promotes
macrophage foam cell formation in WT mice on a HCD. An important
role for NF-κB in the CIH+HCD-induced foam cell formation is indicat-
ed by our demonstration that CIH+HCD induced signiﬁcant numbers
of macrophage foam cells in WT, but not in p50-KO mice. Our result is
consistent with a previous report showing that macrophage-speciﬁc
overexpression of a mutant I-κBα suppressed HCD-induced macro-
phage foam cell formation [44]. NF-κB activation could stimulate foam
cell formation by several mechanisms. NF-κB target gene products, in-
cluding TNF-α, IL-1β and IFN-γ up-regulate acylcholesterol transferase
(ACAT) expression [45,46] and/or down-regulate the expression of
scavenger receptors [43,44]. NF-κB mediates the up-regulation of
ACAT [45] and own-regulation of scavenger receptors [43]. Altered ex-
pression of ACAT and scavenger receptors increases cholesterol uptake,
decreases cholesterol efﬂux and increases macrophage intracellular
cholesterol storage, stimulating foam cell formation.
The pathogenic role of macrophage foam cell formation in athero-
sclerosis is well documented [47]. CIH and HCD synergistically induced
macrophage foam cells and atherosclerosis. P50 gene deletion dimin-
ished CIH+HCD-induced foam cell formation and atherosclerosis. It is
possible that CIH+HCD activate NF-κB,which in turn promotes athero-
sclerosis by inducing macrophage foam cell formation.
NF-κB activation is a pathogenic mechanism of hypertension [27],
diabetes [28], obesity [29] and insulin resistance [30], conditions
known to cause atherosclerosis and to be associated with CIH exposure
and OSA. NF-κB activation by CIH could promote atherosclerosis by in-
ducing these conditions. Overall, these results support our hypothesis
that NF-κB activation serves as a central common mechanism by
which CIH activates multiple atherogenic mechanisms, leading to
atherosclerosis.
A prior study showed that exposure of WT mice on ND to CIH for
12 weeks did not cause atherosclerosis [11]. However, exposure to
CIH for longer periods of time may cause atherosclerosis. We exposed
WT mice on ND to CIH for up to 8.3 months and found no evidence of
atherosclerosis. Our study therefore extends previous studies [11–14]
by deﬁnitely approving that CIH exposure alone does not cause athero-
sclerosis in WT C57BL/6 mice.
Although this is an animal study, the concept demonstrated here
could be applicable to OSA patients. Patients with OSA have increased
NF-κB activity in neutrophils andmonocytes [18] and increased plasma
levels of NF-κB-regulated gene products [18–20]. It is possible that OSA,
by causing CIH, activatesNF-κB,which in turn activatesmultiple athero-
genic mechanisms, leading to a proatherogenic phenotype. The impor-
tant role of NF-κB in CIH-induced atherosclerosis suggests that NF-κB
may be a good target for developing therapies. Targeting NF-κB path-
way can simultaneously inhibit multiple atherogenic mechanisms and
will be very effective. One major caveat for targeting NF-κB is that it
causes unwanted side effects, because NF-κB is involved in many cellu-
lar and physiological processes. A strong argument for targeting the
NF-κB pathway is that a vast majority, if not all, of signaling molecules
that play important physiological roles are multifaceted. To maximize
therapeutic effects and minimize the side effects, one useful strategy
would be to block theNF-κB pathway in a cell-targeted and pathological
stage-speciﬁc manner.With the advance of modern drug delivery tech-
nology, it is quite feasible to deliver small molecule NF-κB inhibitors to
targeted cells at a speciﬁc disease stage.
1658 D. Song et al. / Biochimica et Biophysica Acta 1822 (2012) 1650–1659One limitation of this study was that CIH/HCD exposure caused
weight loss, especially in p50-KO mice. Since food restriction induced
weight loss correlated with reduced atherosclerosis in obese and
insulin-resistant mice [48], the possibility that CIH/HCD-induced
weight loss may have partially contributed to the protection against
atherosclerosis in p50-KO mice cannot be ruled out. However,
NF-κB-mediated activation of multiple atherogenic mechanisms clearly
plays an important role.
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